OptimizeRx Corporation (OPRX) Cash Flow Statement
OptimizeRx Corporation (OPRX) generated $18.4M of operating cash flow over the twelve months to 2026-06-30, spent $112000 on capital expenditure and had free cash flow of $18.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OPRXOptimizeRx CorporationFollow OPRX — free
—
Price chart with a free account
- Market cap
- 172.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.5 | -0.6 | 1.1 | -0.1 | 0.5 | -0.5 | -1.5 | 0.8 | -1.7 | -6.3 | 0.7 | 10.7 | -7.2 | 4.9 | 18.7 | 18.4 | |
| Capital expenditure | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.1 | 0.5 | 0.2 | 0.9 | -0.2 | 0.2 | -0.1 | |
| Free cash flow | -0.5 | -0.6 | 1.1 | -0.1 | 0.5 | -0.6 | -1.5 | 0.8 | -1.7 | -6.4 | 0.3 | 10.4 | -8.1 | 4.7 | 18.5 | 18.3 | |
| Share repurchases | — | — | — | — | — | — | 0.4 | — | — | — | — | 20.0 | 7.5 | — | — | — | |
| Stock-based compensation | — | 0.3 | 0.4 | 0.9 | 0.3 | 0.2 | 0.1 | 2.5 | 2.3 | 3.2 | 5.5 | 15.7 | 13.7 | 11.5 | 7.0 | — |
USD millions · SEC XBRL
OptimizeRx Corporation — questions
- What is OptimizeRx Corporation's operating cash flow?
- $18.4M over the twelve months to 2026-06-30.
- How much does OptimizeRx Corporation spend on capital expenditure?
- $112000 over the twelve months to 2026-06-30.
- What is OptimizeRx Corporation's free cash flow?
- $18.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from OptimizeRx Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.